<SEC-DOCUMENT>0000950123-11-026397.txt : 20110317
<SEC-HEADER>0000950123-11-026397.hdr.sgml : 20110317
<ACCEPTANCE-DATETIME>20110317160043
ACCESSION NUMBER:		0000950123-11-026397
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110311
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110317
DATE AS OF CHANGE:		20110317

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lifevantage Corp
		CENTRAL INDEX KEY:			0000849146
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841097796
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30489
		FILM NUMBER:		11695234

	BUSINESS ADDRESS:	
		STREET 1:		11545 WEST BERNARDO COURT
		STREET 2:		SUITE 301
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127
		BUSINESS PHONE:		858-312-8000

	MAIL ADDRESS:	
		STREET 1:		11545 WEST BERNARDO COURT
		STREET 2:		SUITE 301
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LIFELINE THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20041019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	YAAK RIVER RESOURCES INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANDRAPLEX CORP
		DATE OF NAME CHANGE:	19920406
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a59000e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B><DIV align="center"><DIV style="FONT-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B><DIV align="center"><DIV style="FONT-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 18pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of<BR>
the Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of Report (Date of Earliest Event Reported): March&nbsp;11, 2011</B></DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B><DIV align="center"><DIV style="FONT-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>Lifevantage Corporation</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 0pt">(Exact Name of Registrant as Specified in Charter)
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><DIV align="center"><DIV style="FONT-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Colorado</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-30489</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>90-0224471</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or Other Jurisdiction <BR>
of Incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(IRS Employer<BR>
Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top" nowrap><B>11545 W. Bernardo Court, Suite&nbsp;301, San Diego, California</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>92127</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(Address of Principal Executive Offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">Registrant&#146;s Telephone Number, Including Area Code: <B>(858)&nbsp;312-8000</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt">(Former Name or Former Address, if Changed Since Last Report)</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-family: Wingdings">&#111;</FONT> Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-family: Wingdings">&#111;</FONT> Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-family: Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-family: Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>











<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">








<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left"><B>Item&nbsp;5.02</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March&nbsp;11, 2011, Lifevantage Corporation&#146;s board of directors appointed Douglas C. Robinson
as its President and Chief Executive Officer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Robinson, age 48, is a seasoned executive with more than 20&nbsp;years of experience in
management and financial operations, business development, and corporate governance and oversight.
From July&nbsp;2007 until March, 2011, Mr.&nbsp;Robinson served as Chief Executive Officer of WorkWell
Systems, a physical medicine and workers&#146; compensation solutions company. Prior to joining WorkWell
Systems, from 2005 to July&nbsp;2007, Mr.&nbsp;Robinson served as SVP Healthcare Transformation for
UnitedHealth Group. Prior to United, from 2002 to 2005, Mr.&nbsp;Robinson led Deloitte Consulting&#146;s
newly formed consumer-driven healthcare practice. From 2001 to 2002, Mr.&nbsp;Robinson served as SVP,
National Practice Leader for SynHrgy, an outsourced provider of integrated human resource services
including Health and Welfare, Integrated Absence Management, Integrated Pension Administration,
Workforce Administration and Compensation &#038; Performance Management. Mr.&nbsp;Robinson holds a B.A.
degree in Marketing/Public Relations and Speech Communications from Gonzaga University, Spokane,
Washington where he also continues to guest lecture on healthcare economics to the undergraduate
and graduate schools.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Robinson has served on our board of directors since January&nbsp;2010, and will continue to
serve on our board of directors after his appointment as our President and Chief Executive Officer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We entered into an employment agreement with Mr.&nbsp;Robinson on March&nbsp;11, 2011, which is
effective on March&nbsp;15, 2011. The term of the employment agreement is through June&nbsp;30, 2014 unless
earlier terminated in accordance with the terms of the employment agreement. We agreed to pay Mr.
Robinson a base salary of $325,000 per year for his service as President and Chief Executive
Officer. Mr.&nbsp;Robinson&#146;s base salary will increase to $350,000 per year if, for each calendar month
in a consecutive three month period, the Company&#146;s EBITDA exceeds the product of ten percent
multiplied by the Company&#146;s total revenues for each such month. We also agreed that we will grant
to Mr.&nbsp;Robinson an option to purchase up to 1,610,000 shares of the our common stock pursuant to
our 2010 Stock Incentive Plan on March&nbsp;15, 2011. The options vest only if Mr.&nbsp;Robinson is employed
by our company on the applicable vesting date. The options will be subject to the following
vesting dates and exercise prices:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Shares Subject to Option</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Per Share Exercise Price</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Vesting Date</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">110,000
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fair market value on grant date
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Grant Date</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">500,000
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fair market value on grant date
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">June&nbsp;30, 2012</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">500,000
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">$1.20 or fair market value on
grant date, whichever is
higher
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">June&nbsp;30, 2013</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">500,000
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">$1.75 or fair market value on
grant date, whichever is
higher
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">June&nbsp;30, 2014</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We further agreed in Mr.&nbsp;Robinson&#146;s employment agreement that, commencing during fiscal year
2012, Mr.&nbsp;Robinson will be eligible for annual cash performance bonuses of up to
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">fifty percent of Mr.&nbsp;Robinson&#146;s base salary based on performance objectives that will be determined
by our board of directors with input from Mr.&nbsp;Robinson. Mr.&nbsp;Robinson will also be eligible to
receive the following transition bonus payments: $101,250 on March&nbsp;15, 2011; $67,500 on July&nbsp;31,
2011; $33,750 on September&nbsp;30, 2011; $33,750 on March&nbsp;30, 2012; and $33,750 on October&nbsp;1, 2012;
provided that Mr.&nbsp;Robinson is continuously employed by our company through the applicable payment
date. If Mr.&nbsp;Robinson&#146;s employment is terminated without cause or if Mr.&nbsp;Robinson resigns for good
reason, Mr.&nbsp;Robinson will be entitled to severance equal to Mr.&nbsp;Robinson&#146;s then annual base salary.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The foregoing description of Mr.&nbsp;Robinson&#146;s employment agreement is qualified in its entirety
by reference to the full text of the employment agreement, which will be filed with our periodic
report for the applicable period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Robinson replaced David Brown as our principal executive officer. Mr.&nbsp;Brown will continue
to serve as the President and Chief Executive Officer of our network marketing operations. Mr.
Brown will also remain as a member of our board of directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We issued a press release announcing the appointment of Mr.&nbsp;Robinson as President and Chief
Executive Officer, which is attached as an exhibit to this current report on Form 8-K and
incorporated by reference.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="94%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release Issued on March&nbsp;14, 2011</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">Dated: March&nbsp;17, 2011 </TD>
    <TD colspan="3" align="left"><BR>

<B>Lifevantage Corporation</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Carrie E. McQueen
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Carrie E. McQueen&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer, Secretary &#038; Treasurer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a59000exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: Helvetica,Arial,sans-serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="a59000a5900000.gif" alt="(LIFE VANTAGE LOGO)">
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>LIFEVANTAGE ANNOUNCES APPOINTMENT OF NEW PRESIDENT AND CHIEF EXECUTIVE OFFICER</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Douglas C. Robinson Brings Over 20 Years of Executive &#038; Financial Expertise</B>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>San Diego</B>, <B>CA, March&nbsp;14, 2011</B>, <U>LifeVantage Corporation (OTCBB: LFVN),</U> the
maker of science-based solutions to oxidative stress, announced the appointment of Douglas C.
Robinson as President &#038; Chief Executive Officer (CEO). Mr.&nbsp;Robinson is a seasoned executive with
more than 20&nbsp;years of experience in management and financial operations, business development, and
corporate governance and oversight and has served as a member of the Company&#146;s Board of Directors
since January&nbsp;2010. In addition to his appointment as President &#038; CEO, Mr.&nbsp;Robinson will continue
to serve on the Company&#146;s Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">LifeVantage previously announced that the Board of Directors had opened a search for a new CEO to
take over corporate responsibilities while current CEO David Brown would focus his efforts
exclusively on continuing to expand the Company&#146;s network marketing channel. Mr.&nbsp;Brown will now
serve as President &#038; CEO of the network marketing operations and will remain as a member of the
Company&#146;s Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;We are pleased that Doug will be joining the Company as President and CEO,&#148; stated Garry M. Mauro,
LifeVantage&#146;s Chairman of the Board of Directors. &#147;He brings tremendous knowledge and expertise as
a seasoned executive and having been a member of the Board he has extensive experience with the
Company&#146;s business operations.&#148;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;Given the significant growth and momentum we have generated and the continued opportunity
before us, I believe, as does the Board, that I can bring the most value to shareholders by
focusing solely on continuing to grow revenue and expand the network marketing business,&#148; David
Brown added. &#147;Doug&#146;s expertise in management and financial operations and corporate governance are
important assets as we seek to continue the rapid expansion and growth of our business.&#148;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Douglas Robinson most recently served as Chief Executive Officer of WorkWell Systems, a rapidly
growing physical medicine and workers&#146; compensation solutions company. He is a seasoned executive
with extensive experience in the Healthcare industry, bringing over 20&nbsp;years of relevant industry
experience, including senior roles at UnitedHealth Group, Deloitte Consulting and
PriceWaterhouseCoopers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mr.&nbsp;Robinson holds a B.A. degree in Marketing/Public Relations and Speech Communications from
Gonzaga University, Spokane, Washington where he also continues to guest lecture on healthcare
economics to the undergraduate and graduate schools.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About LifeVantage Corporation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">LifeVantage
Corporation is a publicly traded (OTCBB:<U>LFVN.OB</U> &#151;
<u>News</u>), science-based,
nutraceutical company dedicated to helping people reach their health and wellness goals while
creating business opportunities. Founded in 2003 and based in San Diego, CA, LifeVantage currently
offers two anti-aging and wellness products: Protandim<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, a dietary supplement that combats
oxidative stress, and LifeVantage TrueScience&#153; Anti-Aging Cream, a scientifically-based skin care
product. For more information, visit <u>www.LifeVantage.com</u>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Forward Looking Statements</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This document contains forward-looking statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified
by words such as &#145;believes,&#146; &#145;anticipates,&#146; &#145;intends,&#146; &#145;expects,&#146; &#145;plans,&#146; &#145;seeks&#146; and similar
references to the future. Examples of forward-looking statements include, but are not limited to,
statements we make regarding our plans with respect to the hiring of a new Chief Executive Officer,
management roles and responsibilities, anticipated results of operations and future growth. Such
forward-looking statements are not guarantees of performance and the Company&#146;s actual results could
differ materially from those contained in such statements. These forward-looking statements are
based on the Company&#146;s current expectations and beliefs concerning future events affecting the
Company and involve known and unknown risks and uncertainties that may cause the Company&#146;s actual
results or outcomes to be materially different from those anticipated and discussed herein. These
risks and uncertainties include, among others, the risk factors contained in the Company&#146;s Annual
Report on Form 10-K and its Quarterly Report on Form 10-Q under the caption &#147;Risk Factors,&#148; and in
other documents filed by the Company from time to time with the Securities and Exchange Commission.
The Company cautions investors not to place
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: Helvetica,Arial,sans-serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="a59000a5900000.gif" alt="(LIFE VANTAGE LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">undue reliance on the forward-looking statements contained in this document. All forward-looking
statements are based on information available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking statements to reflect events or
circumstances after the date of this document, except as required by law.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>###</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Investor Relations Contact:</B><BR>
Ioana C. Hone<BR>
(801)&nbsp;432-9000

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>a59000a5900000.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a59000a5900000.gif
M1TE&.#EAN0`J`/?_`)FRQ/KZ^?[\^OK\_$IC>/K\_O[^_CQ:=OS[]?'V^F-X
MB2E+9?W[^='<Y,/2W;7"S/7Z_?[^_/S^_BA$6\W:X]WL\AHZ5OS^_'N3IZ.R
MN_[\_/'Y_5-L@^WU^.+I[4)==/K^_OWZ_`0N4O[\^&1\D4-9:_C\_E1I>N;S
M^8NAM*N]RIVMO$MI@KG)UC1,8QLU2^7Q]K+#T"$X3?K\^OS\^?+]_LK5W?C\
M_/K^_,75X:.UP@(P4W6/HMGHZX&4HVN%FKO-VWR.G.[Y_08M3O?^_K_0V_[^
M^MGF[3%)7<G6X:S!U.GQ]O'T]?7X^EIPA/;\_JRZQ)6KNL#,UCQ4:I.DL_;^
M_H.:J_S^^J.YR76*G&N!E>GU^<38XO;\_+S4XVF'HJW`S_3\_N7N]OCZ_-KB
MYN_R]<O8W_OZ_.#N];7+VK3)U@PT4O7\^LG<Z/[\_N[W^GJ0GEUTB?+X^EEX
MDC)1;)VTO^[U_.;O^?3^_M;@Y=+AZ8B;J];E[>KY_?3\_'&&ECQ9;_C\^?C^
M_.CQ^=SE[M+C]>KN\@LP3=GEZ?KZ_V6#G'R+E.[T]M;@Z3M29.'M\I:IMOK[
M^.3M\?;^_%1RBO3^_*FVPH:>L+G&TM[EZEMXBZ:YQ@(P63109M;C[.W\_OS^
M^**VRV.`D^#I\!]$8M?FZ69R?)2BKH&2GOC]^,[?Z.7K\/G^^L;>Z^OX^HZA
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M[P\Y6YZ\U/W]_?_______R'Y!`$``/\`+`````"Y`"H```C_`/T)'$BPH,&#
M"!,J7,BPH<.'$"-*A&@`G(`(`PT8D"#!(,8(&@U8TP9N1"TC_HQ$P*AQI1&-
M'$.V5`G2`$9_&@?>#*G2`,Z5!7,2K"G!YDJ@`C?ZU+FQ:(1L%R]F+(I0ID\C
M*C,*%;AR:<ZO$;).;7GSJ("D1ZTVM>K-0+^5W*Y]TZ;-IP037295JG(-9%>8
M5H^&[;DT(TZ-1FK5JOG7*L'`@FNJ;>DS)+9L2),6G3PYPN+`,E=N]M8V9@0!
M`K+)C&GS+=F;'%U+&&`M6[;8_;R1(W>MG[9^&OMEPP9B`X5+HE@HU[0BT^;<
MO+/EEMGO,CALFT-&`$[.F_"3V*ZU_Q59/9N&?L!#]I.@+1LX<-I8&\`63GIW
M]+:SA=CF3P(("3C4%1)'$F!CX('H)9@@-A%@4YV!*^7FG6W:6).@-=9(0`XV
MX-BFD7>X#9>=6P*!`((U`_@WP`#9A,.1-=MXP\V,WER3803E"&``$10HXLL0
M0`+)02[_27#-->B(@YJ#,EX35W6Y77..-0;2)0$WX@CW'C;6'"E!;:@)L,TV
M#[98@#8"C""`-29R=$$X[%P7%WNV:8#.`&\4`P-'`ZSCS4CA7'!!?OEU(\Z1
MB(J3X9&7"0".C4<*%XZ%_6!8J9/7T%7AC%]:>%EX'"$JD(HIFEB;BU_&..-N
MY%AS03D,,/_@SQ:7[#.$"$$.44(+1/P7US8:H":=C.K,F*`WZIPSW*4<><>A
M=/U<HXX$P@F[((?AJ(/-"&I:4T`!;KIW'6D2#&J>!!`X<`HN.(6P#CGEG42H
M;>.(4Z.1WBCZ7V_9C%!.7!?\YB!Z3:'G9%PV6B/CE^A]ZHU_WY(SZI=T92A!
MBR^JRHTW8XX4:SG^V`#,$)QP(L(^%E##01&]&JG-.&&.`]V,W&Q#(97#'<J-
M?Y0.O`V&%G:S)'K;C..>=&$*(*TZZ+5GFZ$/#XJ:!!NL@$\6_F@0`CKP6F=$
M.&"'/4['J?Z\KS?8"#`.P-H,7"F!%MI(<VW]<&.I;\/Z!T(!$OO_LS$VX\"<
M33>VQ;;-.>(!FYHV""#@8@;$W'J(-+$,HT`S#13PGS7A6-1A-V3*V!UJX+#3
M>8?KS&BJA=[ULTTWX3C8#9/H"6U1TF.34S-JP&K@NQL/XQ`.:@9L<,H+3O@3
M`#8;]]--X!$02"":`H@M0'PT"U?W-8*&X_K/<!>=#:)IAW/BF'@;*&@!ZO2-
M3K!)IW8;M6..Z;O:4.D8QAZ'W#K!+AYPA2$\P(@"V(TD([B.1L0Q)G&(PPT"
MR%$YTE&.$6`C==S86Z=(`ZQQ=&A@NG%6-MB1(]1HX&#7$)H`-#`.T+D!>``:
MGHX@$(P7*,`?,YB4@WJW'NFQYSU`?$^@_YR$H0H=25`7Z`<#U[.Y;C"@'+Y)
MVPC8<:)NG(<DI`O'`&8DD`(,X!SGB)4`]A,M\3#00!H8@`FJ\"5VS`H#:[@5
M,-0`@9`\*1WO28<V(`"!,1C0>1J8"RO0]$1PR`QQYSB#.<)ACFZ@9R04-!0Z
MS(B.<,R`%3?0AA'`,2D+N:4;V@A'*EBQ$FR$0%':8(<YBD<%&=P0!S1X3PN_
M4:F5Q#(",X@`.&)9$FZ!(Q+7&,`,9E`AF\5I'.<)'`/,`8(!*(D!XLK&.`9`
MA`$P`#7F`$<ALW$.T@A$"/FPPS3D$(YQN$MWW"#'.L[QFS.\X1:WF,8&9N"/
M)6``2+9@01'D8/^"%1WI&^4`!P[\L`H]-"`/NG@#"`"G#1#TRAHA@-T,L-&-
M;VPC!+!BP#BT,0`3G0,<YE"'%XGPA)+ZH0I$,$$XRH$J$_T&!'J9A$QO<(9V
MK&,`..#(&Y+A2G\\H0N"P,$`SC"E;\QND2:X@0DP60!V-,X(Y3"'%W-TCD2<
MX09=N,&*!F`.`3!@!H*0@.^<F$!SK#$,2;T!(\V!``9T2`/;^(8_VJ&#**P@
M&38HBFY8M9LD&:`,F+!K%*3`!'_`@`=QY`0P4J`$,.#"`4OXTEV.$(-+9($6
M6=B%#B@@!W\,`%PF\$`FED`;:XR#`>@Q!P77`P%)$,(0PS0`'AY!`2#_8*(%
M23@"GP8`G-828AF1`($0]``$%6PB!@U@@@2(8`!T4*V53D"!'JJA!SUD@A&T
M\49_[M"((MRV")X0@@1J40X)?`L$VJ#!.`SP!@K$0`5@0*XKBC*`)63"$"$8
MQS>69(`.V``7\&V!)T!@@&'.(%@,Z(8_$@","2Q@`O5@+CK2N8YWS>@<_A#&
M#R;P#"1DP0.&Y<$A1+"#?3P#$,?H1!;,``)_=&`3)#@`*7Q!8U)(@P,KZ(`$
MU&$`)EA"`2MX@P3,D<LSM$6:Z#!`)NKQ!US(`01%:(8"3@"(3I2```J(QR/^
M@^$.J.`/4,"#)%+`@1(@80*=.$$S'!"&)_A$_PB0F``Q*$%G2IP@"+PP@=_R
MD`PMG.`#)9C"!YRP"P?\9T5>'(`_JI"+()R@$PX&!*%S@(<:;((64&@"#8#C
MCPTXP`<$./,"#G""#&S92-AP:S;\4092!"D+50!!M+SANQI=PR<-H,2MAJ"`
M3(1X#27CQ`YV(`*5$6D#*B``*79@,A$X6P1K``8\*C"`XJW`$0I0A6<#^@UN
M],,<W]A("][Q#ER((0,<.#,2KCP%),@`'SR@`!O]88AZ3&$/?`A")UQ``"=0
MH@3$0`(S'/`)`M>`"J2@Q@+4/0%Z2.$&$L"$*5PP@0E<^1TND,$$YD!']GQ1
M`@EX@!.(,8$I$(`%9O]&`CW4,(M+T.$5<HC`.(H#!@54_`1.X,`4B%$"*^BA
M!@N])LBFX6H@\8"-J?(=>LZ!D09P8`C$5D`/?BT"3N1J""=P0`V`P($U/'L-
M8"?VR0@`CT$XMP4$Z(0E_#$&`2"@&^QQD#_>\(H),*,!*%B$(TZ0!2I`X0&6
MH,(?I.$+##1"SY(8A@L4X8,%..$58,B%`Z`0!$=,@!9\0,9SB7$``#CC%*"W
M1";^DPQ\E(`6K\`"+J"P`AX`@AAQ2((_RA&?::C@!,0@P!XV@0DI0.$2''"!
M$[`PCP7L(0$7H"8F3C`!%J0@!DD``CPPX((%^&#`88P5JTEA]2'\(:P<42'_
M-D02#G_D>M=2#_&(=V`+"Y!<!B1H@QZT8`%<B4`:<U"$)@Y@BZKOPPDYH&>$
MP`,RD`5[XW;?P!ZYD6$D,`&0T`&?4`>OH`9\@`)-T`40D`^JD`*D``@KL`3^
M8`Q6,`'`,`64$`-B4`,_M0'"8&](```H@"Y48`%Q@`>N\`:,P`1-\%D2(`7U
MD`&-@`)"D`!RL`'54`<?\#^&\!(@T`(<,`$<``;&L`&"$`E-D`\MD`4F2`G/
M8`4;D$&Z8',<H`0H\`E)U0&ZP`/2H'9`9PYNY0]$%R1PP%S9(#6I<0$2T!;G
MMP.\YFN'U3]K<`P\L`(ZD`$M@`918`%0MP8LH`-)_^`)#:`"FM!_0T`*]<`(
M_M`$*N`"@&`&_L`M*8(A&@$%)<`".4`$@B`)Q@`!+;831'`+N[``"L`+]'8)
MOF`!')`&KM!B.0$"B+`'$W`">F``!]=37($1Z,0$QJ!0'3$0(-`!\#`%[Q`#
M>;@%S$`*<=`"$&`8_A`&9)`"@+`/TG!\5%,/2,`!,?`&`I$F!F`"JH`!$T`"
M#2`!.%)^K88K0Y`%..`/X'`%^5.'VB`QYX<KZ7=8<70(E%`$+280NJ`)0+(#
MP*`""RD0#L`"NT8`?-!BNA`'+[`+!D!"[+`1VE!/04`,PR`$??$1X*`8[\%I
M9/`!4\`N2W`)%F`!&5`#L_^!6@:@`1*`!SGP#C*@!D3@!ZUT0Z@1"080`B$@
M$LUH$P)``Q'@.X85"\2P"T)0`$"`!%.@`D^`$^C`-\@B$"CP`T-@`9?0!";0
M`(#@`IO0E:@Q`@B@)A)@`^D&"57@#]F0#MLGAR`0`1?@C^]1A]1B?KKF;`H`
M8H.`6$/`B&E01U?@#Y@@#5#G"Y<``SZ!A_X0#<ZP#U5'"D!0`P;P!'OP`G$0
M@P.@$N7B#UQ``!-`C:LT!GVI&%P1$QU``G2P`B"P!%;@"R60!]5V#@.@#J?5
M#T_`!S]`#0#P"<5X0VZ@`>+`#06@2'I%#@:@71>P$W@0!9=7`7@`C\R0!U_B
M.^+_.3C<8``/(`W[\`H;(`<K,&=\X`\10`[B8!NH"0.[(`-:<`L2X%5_10K.
MEH_,U27]H'1.@FN%*0*':5AP-`2'P`)```$20P1Q=BL'$`.?T`0!P`9\9``.
M<`"[!@!OX!,M0`?X``0@P`!&P`H#H`W7T)X$@`8$9@[6\`0;D`",L`3&,`MB
M@`*NL`5J^`IAD`\CJ`"/P`INH0W"*0#]4``P8`748`5;@`=%B1/G`2[:,`.S
M,0,W(`<=(`8P\*5+0(2;0`<*4($<X`C!`(+]\"Y\)0[HX`\5,`=F:0>/P`QF
M.0B?.`"QAH?+M0%@@`0$T`82$`EG$8=``@<M-B/H4&$3_]87A`EU"#IUAX4K
M^=28&N`/JQ`$MK(/E*`"9F`#-I`#7,`%K1`#%LF'S"`)`E$#6?`"EX`"`F`$
M9X*I-D<%>'`&(1``$#`*1:`#EP`'6<`#PY`"`*`$)+``KP`!@V`%"\`#6Y`*
ME7(%!C`.Z4"='0`)+X`!2U`%SM!3$M`-W2!,-%`.%Q`&,&`#@0<'/+"N>[`"
M8&`%TA`'JJ`*@/`.8-`$_A`"WW)>(-`;"Q:+>]`'%,`!I,`/*,`$T[`%6]`!
M^;`,99``=E`$'X`$*N`/@5`._?F?64`$_H`H^>(E!GHK(D`"DKJ@E0JA_D`&
M6L"9G"`-E"`*"D`"HC"S)$`)Q__PGQPP"CCA#QDP`9K0`&-0#GWI#U+P#A^`
M"00F`6&@"LD0!VN)!$C@`E`[!2<@#1.0K+JY`!BP!4_!#E<0'];@!@;`"-BJ
MK5500Z^D#0'0'I$`#A)0`5B@!1^`#U$+M2Z`#T8[`92@"EQ`!P2`"76T#8@R
M$B_#``8``:_0"59P"USP`:20`FJ`"6H0`Y%+N3'0`FD``#N7`080"`A@`'90
M=$.`J")Q!9V##9J"#8\:=9(J8B)0J=5F?B3@=9P`=FM@`6M@"[JKN\\V!"S0
M`P;`"OY``4X`""K`!&I4/%'@",Q0#)X5!I[@`^U&`+&P!]8;!'_``8#@?LDZ
M"+L@#</_(`>@,`[A<`7LL$7;T%]ENZW=>D,2,`._!`X8NP0K8&;OH`"[8+VH
MD`4*\`X38`$*T`9]^[<0&C]A(BMRD+B+ZP5TX`L'H!P0#,$GQP+`@#+)@$.?
M>X^XLK$&H`U7X#F<-#R/:C(%B5BORP)I$+L-,+LE@RO]$R3XR*"X\@Z^)KQO
M,()[X`$IY0]'0`*.``GB40"#D`(+X`@^H`:M4`'%4`R$T`@.``9.@*QRL*P+
ML`L)0`-J`PH1``(F(`[J^P)PL*U32B<!@!D2$`-)2`*60`$>,`J/,`IYD`-J
M$`NRV`"J(&A@T%GP$S_@T&G#L`!6@`)>,`46(`T',`53``@'_W``BKS(@$`'
MTO`!:Q<`(P"'HHNH#?(>8:)"(SP$)%M//(!/*'P&;N`/F4`+G&D+SS`'?R`*
M6O`#L/P#]O`'?T`+?T`%AA`!<F4`,0`('-`"3R`!30`%@!`'>>`/Y"`'4@`(
M$T`%NA`&+8/,!6`"&V`%=+`'$)"UN[`!H*`V<E(`;T&V,@`',,"M/45K$1`)
M"J8+6D`,S*`*"5``_?$?!?`$8:`")M@(,,`!G5`/CR`!VR`.]U$[UN`/GD`)
M9KD%.5`"$^`,0"`%+0#14C#14M![$)T+'D`.,).Q&TR'^3-6P>(/>:!K)`QB
MQ@`'<91/+3`&&F``2S`,/\()+*`$U?_0`S;=`YE@TZ-0`9G@`9+0!"OD$WE`
M`IV0`I^`J8N`!*_0E2Z]`C+@!'H`GQ&@#>80`0S`DQ+@<C"GS7+`#B%0U=B`
M.`]SK3*`"C`@I3W5#^,PU3Z!"8#@".PB$M_@#0-P:[7@#P\`")3P<\,P`7&0
M`PN%*#,B'OY`!)NP`/NP!W+0`,P7`Q.Y$'X2;JTFAQR+#:1!&E`R?B--,CO0
M:_4$!Z(,!$U@`""`!RO@:CMP`$I0`P>Q(U1!`[,#',:0N"0``_Z0"R=0`A6[
M$:.P!S)@!<;@#P(@*.R0#0R`#4^`!S^Z`6(`KSX@!P,0`N'&(1%P#1)`UF:-
MUC?D02G"$9;_('S'G%(#\`WF<P4C(`%0X`)[_01JX`+2``"8V$R_`2,:P0>Q
M8`N^4`\)X`%VF@+YX`^N`@JF2S2Z8P#98`XV8@Y[>:B"T!\^%!,B3=*>/'4G
M[77Y!`318`"*!@0C,P3[$`NJP!+TZ`\FD`=2,`I$H,OI6Q1R$`,G,`5Z0`37
M%@<4D*\2,`H^\`+.8`?\Z!_:!!]$H`PD0`KJ"0-_;,5)=@[HL`WR>P[7#0GC
M;`Q2:D/^H`T1D"(%0`3PX`)Q`&)=8`+<\`W9,``T8`1=X`RPIP<F@`9Q8`&4
MP"L:P2`^`0(50`7`X`M=V`1,$`S$H`E1[10&<@;H<`::0X\"8`X#_W`6DPTD
M),`%9C"JD#ZJ#J`*<J`'NC9L)>QL%SX`5^X/CZ``0'((]X8(34#/2R`%0:``
M47`$)O`;I+TW>I`%G8`%,!`+4_`*P<T`(%`,E_`"/#`+!B``>CH`"!`!FM,"
MKP>D^7#D<E`7_5`L7G4.ZAOE(-"M<=`?!H#@_J$#:=8`.&0.KY,C&*$'"K`&
ME)`'8Y`(F\":)!`#C]`$!6`.K>4`>\`"E,`"QS`,31`($ML)=;`%14$.Y]`/
MW]!11"`)>6`(M2"CE]IJ+4P*$1SQ'_`#%-`#A3D$FM"Z*>V@39"7I(T%2``D
M(C`!/*`"7$`!1>`,+("[4Y!C1L+%\LP(4/]``)J@!"S@!%)@`E8-`OF@`Z1P
M`&F`DUE>`%<N!$<@"B]@`500I,X-W2!1%.6``.OPQ1A@"`8`.02PBQJQ,SWX
M#@NP`AL``A<P`VI=-Z-P":2P!L8\`.2P!.M.#!_@`X_E`#&P!TZ`#S5??-C,
M!GUP"><(!EO@$RQB`&Q0`[.0`8N`"[(`G6?@#Z%;=2W\PE<W!%/0`A7P=+CR
MR7\X!"=K``/O#ST`TR1F"\1P#`0`##*V!OWS/\:@X41`!$5A#7I`"T@P!U-@
M!;H0[`R@MC;``K[.!:ZP`7S4`8^0!#]@>5?;!-/0]!*`*M=@&PZ4`%!>]08@
M!8Y`L<H@_'+`"!#_,`LER0)J@`(;,`:PH/QZ8`4?L'`*D`<I/@;3\``*`+6=
M\`&`,`4N,`5_D`OR4'SJ"1`%"N31-(&#"AAL($!@\X9"BG<E,CQY(T:,MS*D
M.&W<,>20"!$[1'8<TJG%*"=#5"KHX0\&CT-#UK!(T\6`.G0&3.3XX8L32$ZV
M;'$:28Q2##D2^@U@VLT`HQ4R?'W`E<!?MDC9:!A*YF+!#QT.&E#`%(P$$E&4
M.M6#,&T7DEUR(F33)N%:A&XA_#%9\0*#(0.9F!'C8`E(K@>X$('`],Z"DRA`
M>%%PL(G6%`Z*Z#C1(V@`C0$='-1S`LCT!TW!>#79$@2)LPW6SFQ0<6("_X%3
M4BA0CJ'%$9)%>1)0>("I21EB*I4O9S[EY`GE<5H:6Z2<`*8;V+2=<YJ@A:@%
M'4&"5$E*BXI'(+YMZV9NV[9S36Q,H*8@28$(YK292S?&4[,ID'#$"684(,`1
M1Y@!X@LDZCG.APE0:<(<NK@AQYH!QC""B6"H@<,0?R#`A0`9ICB!GA(4L`&$
M)58@8`)\3BCPA!(Z<0(*`%PXH0$)!F"''6V:0*2%30````P'5FG"GT>TF`">
M)[#Q!H1'X'%B`B1.((&$.$H0,`L'GB@#DWI68"(!45A@@1(6.."@33779`&8
M6!J0I)XX7P&1$7@H(8"281J(I!8!L@%GG$0<JO\CE@-\&8*:-8XA(8H&IGDB
MDG[&80`;`[Z900(Q?*!DDVG\B<``V:XQ80P/5."!!3I<F(*%+*)HY`TEAL%D
M@`1BF`>*,0(0H!]TMK$&A+N:D.(/%3KPQY\.6HB%A0\.X`"23"R\HP4KY@"D
MDTX(("$%!USA91=()/'&!`FRB4"")S;H8)I!MH"`*7\H8&$!-4"XXH)4!BC#
M`6=(^$`:.@Y@81<P/)&CEF6D@,02)JQI(P>,D\B!"XW;2(*+'#1691HYA,'8
MC$R:Z`>"49)(P@QAF#AGG'($$(`!;PQX8HM&I-`ABA7JB*$-&`JPRYQ^NAF'
MTWZ^@9<0"@P9()Q^O+'_YAMQK#'`@#>$<0"73<``0H\[3`!!#$*6N&:`)0B1
M^HQL^I%;`@FV'F`9:&`8P(!GA?!$BAAB<,"#)K:68`-=<HAADTW42.*1,"1@
M)!,E#3CGV1X-.-4?OLVQANX5)CC!$P-&`(>=4V%9@BS&8RAB%"%`T)S5/,@8
MP!^Z<]>=&VYTUQT$=0P@1QP#)"@`!`EZW_H;<\H!AU,#<I;`!`CD2&`#$_@V
M0&[NN^^''&X,0/Z;;[AG[YMS^*:[@"?8K;O'S[=67BGOJ_;FFO"WQN:,?HH'
MP80G/$$"G/,&S;96`%A`X`G'6U\!^(8-=LP@%P[(Q[-P5P!V7<X?>J"$!78!
M_P$C,``<_;"&A8J'00@4@!N<0]76QA"-,6AO:S.D(0UM%@$<9L-FV\@9#<_1
M/P-@0XC8D!OYI/<L;.#05$3TGEVX=S\06,-[V\`&=ZXQ0PG@,(?@*,<%R)&S
M^TE`BO636P^]X8VF?>,"-93`%\^!#0&`XU1;8^$%PE'"=6CN!DQ@!@$N08$W
M&`T$("`""(:S"&*P@`M$&.(3KSC'K7$Q;EOKQS;XY@^;93*36M1B-L;QR7%H
M`!M.Z8<0MQ8!(D;OC*M,8S8X-0YWH1*.W:@?W2HI`"%F8XSF\P8YY!9$;'`1
MEMD(AS;>E33V]$.,9!PB);4F-U-NSQOH(%_5#*`-[O\9P),"J,4(LD&./!K!
M!&(@`3&00((ZY((0HQC%$2@`!69,P!$ZJ`$1Q%$U[T7@>>#;WA"%",1GV6^5
MO:SAUM"!#MZ1@Y_],`>%#!4WN5U#HF>46S?*<=%B7N`"$O#&.K912S%^8YAW
MG*(XN`'-;+BR:LD;@-&N%@*8:L,:N^0>-E*J4O(MTZ8/E2GYOM$-XPDD?-@8
MA\U&((!>=@,<U[!####PC@E,P0E9&,8N,,`,+[TC&)(0X_TD>HUL;DT=8SVC
M3<%ACA]^`XG^_&=!+7>.F<KMF>3+)1/[\=6XEK(;GF1'.#1Z`6\DLXDA71I=
M:%I)DZ+4E:X4(UI#FI=NR/35L*6\*1'1)U/]8:,<YAC`.=#8/V5*8*RE+.H(
MCBH.<C!/'!+`@SS`H(4I$(,8I*#M!%P0!R@8PQ\TF`$YU/'5FA*QET#<*?J:
M]BQ-:O*F-TUN)G]90R"2L7^<$P`L<0C'80VVDAI`XS*[]]'M@;:4-EMN-NI&
M0^]*EY+<0",-O7$.=*@C?\_J9$J)B$/XDD,"&@C!-XA0A2?8(0D`X($6M)"%
M%*1!'F$@0C@B\(TOUD]3H=2<)U-)0W_\0\,;YG"'/?QA$(=8Q",F<8E-?&(4
(IUC%)@X(`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
